EverHint – EMA 10/30 Crossover – Top 14 Buy and Top 5 Sell Signals for Sep 08, 2026
Excerpt: 19 signals (from 62 total). Healthcare leads (14). price range $3-$412. 3 with insider selling.
What This Signal Is
Detects fresh crossovers between the 10-day exponential moving average (EMA10) and the 30-day exponential moving average (EMA30), generating both buy and sell signals. Uses two EMAs instead of EMA + SMA, making it more responsive to price changes and better suited for capturing short-to-medium term momentum shifts.
Entry Criteria:
- Buy: EMA10 crosses above EMA30
- Sell: EMA10 crosses below EMA30
- Minimum ADV: $40M (liquidity filter)
- Earnings buffer: 7 days pre/post earnings
- Fresh crossover: Detected on today's close
Holding period: 1-4 weeks | Risk level: Medium
Market Context
Equity markets are showing broad-based weakness on September 8, 2026, with the Dow Jones leading declines at -1.18% while the Nasdaq holds up relatively better at -0.31%, suggesting large-cap value and cyclical names are bearing the brunt of selling pressure. The divergence between indices points to selective risk reduction rather than a full market flight, which can create mixed conditions for momentum-based strategies like EMA crossovers — trends may be intact in growth-oriented pockets even as broader sentiment softens.
The VIX spike of +8.19% to 15.72 is the most critical factor for EMA-based signals today. While 15.72 remains in a historically moderate range, a single-session jump of this magnitude signals a meaningful uptick in fear and intraday volatility. For EMA10/EMA30 crossover strategies, elevated volatility increases the risk of false breakouts and whipsaw conditions, where price briefly crosses signal thresholds before reversing. Traders should apply tighter risk management and consider waiting for confirmation candles before acting on crossover signals generated in this environment.
Healthcare emerging as the top sector for signals is a notable and contextually appropriate development. In risk-off sessions characterized by broad index declines and rising volatility, defensive sectors like Healthcare tend to attract rotation from more cyclical areas, providing more stable trending behavior that EMA-based strategies can exploit effectively. The 62 total signals generated suggest reasonable opportunity exists, but the day's conditions favor selectivity — prioritizing signals aligned with the defensive rotation theme over those in more volatile, momentum-driven sectors.
🟢 Buy Signals (14 of 14 total)
Ranked by RSI (lower RSI for buy signals = more oversold)
| # | Ticker | Company | Sector | Price | Insider | MCap |
|---|---|---|---|---|---|---|
| 1 | ABEV | Ambev S.A. | Consumer Defensive | $3.06 | — | $47.2B |
| 2 | APPS | Digital Turbine, Inc. | Technology | $11.30 | — | $1.4B |
| 3 | ARW | Arrow Electronics, Inc. | Technology | $217.41 | — | $11.1B |
| 4 | ASX | ASE Technology Holding... | Technology | $39.79 | — | $87.5B |
| 5 | AVT | Avnet, Inc. | Technology | $92.42 | — | $7.6B |
| 6 | CENX | Century Aluminum Company | Basic Materials | $47.95 | — | $4.7B |
| 7 | CRWV | CoreWeave, Inc. Class ... | Technology | $99.83 | Sell -$780,393 | $54.5B |
| 8 | IREN | IREN Limited | Financial Services | $46.93 | — | $16.7B |
| 9 | MARA | Marathon Digital Holdi... | Financial Services | $11.83 | — | $4.5B |
| 10 | NBIS | Nebius Group N.V. | Communication Services | $243.88 | — | $58.5B |
| 11 | PLPC | Preformed Line Product... | Industrials | $411.71 | — | $2.0B |
| 12 | QCOM | QUALCOMM Incorporated | Technology | $174.09 | — | $182.8B |
| 13 | ROIV | Roivant Sciences Ltd. | Healthcare | $41.48 | — | $30.0B |
| 14 | UMAC | Unusual Machines, Inc. | Financial Services | $25.98 | — | $1.2B |
🔴 Sell Signals (5 of 48 total)
Ranked by RSI (higher RSI for sell signals = more overbought)
| # | Ticker | Company | Sector | Price | Insider | MCap |
|---|---|---|---|---|---|---|
| 1 | ADSK | Autodesk, Inc. | Technology | $212.21 | — | $44.8B |
| 2 | AFG | American Financial Gro... | Financial Services | $141.01 | — | $11.7B |
| 3 | AMRX | Amneal Pharmaceuticals... | Healthcare | $17.05 | — | $5.4B |
| 4 | BALL | Ball Corporation | Consumer Cyclical | $61.02 | — | $16.2B |
| 5 | BAM | Brookfield Asset Manag... | Financial Services | $48.87 | — | $78.0B |
Field Notes
Sector concentration: Healthcare (14), Consumer Cyclical (13), Technology (12)
Insider selling (7d): CRWV (CoreWeave, Inc. Class A Common Stock, -$780,393)
Data coverage: 4.8% insider (7d), 0.0% congressional (30d), 0.0% earnings, 8.1% news (7d)
Peer Analysis
AVT (Avnet, Inc.): Leads 5 peers: NSIT ($157.34), PLXS ($249.90), SAIC ($127.55), DOCN ($126.69), PSFE ($6.52)
Recent Headlines
APPS (Digital Turbine, Inc.)
- Digital Turbine: Unlocking The Value Of Its Distribution Footprint
NBIS (Nebius Group N.V.)
- Palantir and Nebius Team Up — Bad News for Michael Burry's Short Bets on Both Stocks
- Why Nebius Stock Jumped Today
- Nebius Shares Rise Nearly 7% After Key Trading Signal
- Here's why Nebius stock is soaring today and what to expect next
Vlad's Take
Today's signals: Strong sector concentration in Healthcare (14 signals) suggests sector-specific rotation. 3 signals showing insider selling warrant caution.
Trading tips for this strategy:
- Entry timing: Enter on pullback after crossover or at crossover close price
- Position sizing: Start with 2-3% of portfolio per signal (swing trade size)
- Stop loss: Below recent swing low for buys, above recent swing high for sells
- Take profit: 5-10% target for swings, or trail stop at EMA10
- Time stop: Exit if crossover reverses within 1-2 weeks (failed signal)
Risk warning: EMA crossovers generate more signals but higher whipsaw risk in ranging markets. Use with trend filter (price vs SMA200)
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/
📢 Enjoying the updates? Liking, sharing, or subscribing helps bring this analysis to a wider audience.